摘要
[目的]比较万古霉素及利奈唑胺在体内不同部位金黄色葡萄球菌（SA）感染取样的最小抑菌浓度（MIC）及抑菌效果.[方法]检测万古霉素和利奈唑胺对115株不同部位（痰、血及伤口渗出液）分离出的SA包括耐甲氧西林金黄色葡萄球菌（MRSA）的MIC值.[结果]MRSA检出率为64.3%.万古霉素及利奈唑胺对所有SA敏感.万古霉素在痰、血及伤口渗出液中的SA的MIC ≤0.5 μg/mL的比例分别为77.8%、51.5%及40.5%.利奈唑胺在痰、血及伤口渗出液中的SAMIC ≤2 μg/mL的比例分别为82.2%、87.9%及91.9%.[结论]万古霉素在治疗呼吸道SA感染较血行及皮肤软组织SA感染的效果好,利奈唑胺组在治疗皮肤软组织SA感染优于呼吸道及血行SA感染,在皮肤软组织SA感染中利奈唑胺可作为临床的首选.
[Objective] To compare minimal inhibitory concentration（MIC） and efficacy of vancomycin vs linezolid against staphylococcus aureus（SA） infection of different part of the body. [Methods] MIC of vanco- mycin and linezoid against 115 strains of SA including methicillin resistant SA（MRSA） isolated from different sites（sputum, blood and wound exudate） was measured. [Results] The detection rate of MRSA was 64.3 %. All SA isolates were susceptible to vancomycin and linezolid. The ratio of vancomycin in sputum, blood and wound exudate with MIC≤0.5 μg/mL was 77.8%, 51.5% and 40.5%, respectively. The ratio of linezolid in sputum, blood and wound exudate with MICμ2≤g/mL was 82.8% , 87.8% and 91.9%, respectively. [Conclusion]Vancomycin is more effective in the treatment of respiratory SA infection than SA infection in blood and skin. Linezolid is more effective in the treatment of skin SA infection than SA infection in respiratory tract and blood. Therefore, linezolid can be considered as the first choice of skin SA infection.
出处
《医学临床研究》
CAS
2012年第4期684-686,共3页
Journal of Clinical Research
